The World Bank. High income countries: OECD. Available at: http://data.worldbank.org/income-level/OEC. Accessed 14 Jan 2016.
Anderson GF, Hussey PS. Population aging: a comparison among industrialized countries. Health Aff (Millwood). 2000;19(3):191–203.
Schoen C, et al. A survey of primary care physicians in eleven countries, 2009: perspectives on care, costs, and experiences. Health Aff (Project Hope). 2009;28(6):w1171–83.
Pfuntner A, Wier LM Steiner C. Costs for hospital stay in the United States, 2010. Agency for Healthcare Research and Quality (HCUP), statistical brief #146. 2013. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb146.pdf. Accessed Oct 2015.
Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2(11):659–66.
Herndler-Brandstetter D, Cioca DP, Grubeck-Loebenstein B. Immunizations in the elderly: do they live up to their promise? Wien Med Wochenschr. 2006;156(5–6):130–41.
Centres for Disease Control and Prevention. Active Bacterial Core Surveillance (ABC’s) report: emerging infection program network, Streptococcus pneumoniae surveillance report. Atlanta: Centres for Disease Control and Prevention; 2013.
Insinga RP, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748–53.
Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833.
Esposito S, et al. Vaccine-preventable diseases: from paediatric to adult targets. Eur J Intern Med. 2014;25(3):203–12.
Kimman TG, et al. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine. 2006;24(22):4769–78.
Eilers R, et al. Assessment of vaccine candidates for persons aged 50 and older: a review. BMC Geriatr. 2013;13(1):32.
Centers for Disease Control and Prevention (CDC). CDC vaccine price list. 1 May 2015. Available at: http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/. Accessed 4 Jun 2015.
National Health and Medical Research Council (NHMRC). The Australian Immunisation Handbook 10th Edition. Canberra: Australian Government Department of Health and Ageing; 2013.
Newall AT, Jit M, Beutels P. Economic evaluations of childhood influenza vaccination: a critical review. Pharmacoeconomics. 2012;30(8):647–60.
Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making. 2003;23(1):76–82.
International Longevity Centre UK (ILC-UK). HERON. Cost effectiveness of adult immunization strategies: report. 2013. Available at: http://www.ilcuk.org.uk/index.php/publications/publication_details/adult_vaccination_a_key_component_of_healthy_ageing. Accessed Jan 2016.
Ogilvie I, et al. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: a systematic review of conclusions and assumptions. Vaccine. 2009;27(36):4891–904.
Postma MJ, et al. Further evidence for favorable cost-effectiveness of elderly influenza vaccination. Expert Rev Pharmacoeconom Outcomes Res. 2006;6(2):215–27.
Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics. 2013;31(2):125–36.
Newall AT, et al. Economic evaluations of implemented vaccination programmes: key methodological challenges in retrospective analyses. Vaccine. 2014;32(7):759–65.
Barnes M, et al. Acute myocardial infarction and influenza: a meta-analysis of case–control studies. Heart. 2015;101(21):1738–47.
Grutters JPC, et al. Acknowledging patient heterogeneity in economic evaluation: a systematic literature review. Pharmacoeconomics. 2013;31(2):111–23.
Dorrington MG, Bowdish DM. Immunosenescence and novel vaccination strategies for the elderly. Front Immunol. 2013;4:171.
Grigsby JS. The meaning of heterogeneity: an introduction. Gerontologist. 1996;36(2):145–6.
Lelic A, et al. The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PLoS Pathog. 2012;8(12):e1003076.
Weinberger B, et al. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis. 2008;46(7):1078–84.
Shapiro ED, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med. 1991;325(21):1453–60.
Castilla J, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013;18(5) (pii:20388).
Oxman MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.
Ultsch B, et al. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013;13(1):359.
Pawelec G. Immunosenescence: impact in the young as well as the old? Mech Ageing Dev. 1999;108(1):1–7.
Panda A, et al. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol. 2009;30(7):325–33.
Olivieri F, et al. Toll like receptor signaling in “inflammaging”: microRNA as new players. Immun Ageing. 2013;10(1):11.
Schmader KE, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320–8.
Nobili A, Garattini S, Mannucci PM. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbid. 2011;1:28–44.
Moberley S, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1(1):CD000422.
Marengoni A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–9.
Constans T, Alix E, Dardaine V. Protein-calorie malnutrition in the elderly: diagnostic methods and epidemiology [in French]. Presse Med. 2000;29(39):2171–6.
Bourée P. Immunity and immunization in elderly. Pathol Biol (Paris). 2003;51(10):581–5.
Clegg A, et al. Frailty in elderly people. Lancet. 2013;381(9868):752–62.
Mitnitski A, et al. Relative fitness and frailty of elderly men and women in developed countries and their relationship with mortality. J Am Geriatr Soc. 2005;53(12):2184–9.
Rockwood K, et al. Long-term risks of death and institutionalization of elderly people in relation to deficit accumulation at age 70. J Am Geriatr Soc. 2006;54(6):975–9.
Ridda I, et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine. 2009;27(10):1628–36.
Yao X, et al. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine. 2011;29(31):5015–21.
MacIntyre CR. Elderly vaccination: the glass is half full. Sci Res. 2013;5(12A):80–5.
Ridda I, et al. Predictors of pneumococcal vaccination uptake in hospitalized patients aged 65 years and over shortly following the commencement of a publicly funded National Pneumococcal Vaccination Program in Australia. Hum Vaccin. 2007;3(3):83–6.
Ultsch B, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics (Epub 17 Oct 2015).
Sisk JE, et al. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med. 2003;138(12):960–8.
Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–14.
Lexau CA, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. J Am Med Assoc. 2005;294(16):2043–51.
Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis. 2000;30(6):931–3.
Prince MJ, et al. The burden of disease in older people and implications for health policy and practice. Lancet. 2015;385(9967):549–62.
Lang PO, et al. Immunosenescence: Implications for vaccination programmes in adults. Maturitas. 2011;68(4):322–30.
Smith KJ, et al. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in US older adults. Am J Prevent Med. 2013;44(4):373–81.
Drummond MF, et al. Methods for the economic evaluation of helath care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
Pradas R, et al. Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model. BMC Infect Dis. 2013;13(1):175.
Lal H, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.
Lambrecht BN, et al. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol. 2009;21(1):23–9.
Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine. 2008;26(26):3197–208.
Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494–500.
Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices. Recommended adult immunization schedule-United States. MMWR. 2012;61–84.
Andrews RM, et al. Influenza and pneumococcal vaccine coverage among a random sample of hospitalised persons aged 65 years or more, Victoria. Commun Dis Intell Q Rep. 2005;29(3):283–8.
Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect. 2009;58(6):446–58.
Australian Institute of Health and Welfare (AIHW). 2009 adult vaccination survey: summary results. 2011. Available at: http://www.aihw.gov.au/WorkArea/DownloadAsset.aspx?id=10737418286. Accessed Jan 2016.
Eilers R, Krabbe PF, de Melker HE. Factors affecting the uptake of vaccination by the elderly in Western society. Prevent Med. 2014;69:224–34.
Ridda I, et al. Factors associated with pneumococcal immunisation among hospitalised elderly persons: a survey of patient’s perception, attitude, and knowledge. Vaccine. 2008;26(2):234–40.
Beutels P, et al. Seasonal influenza vaccination: prioritizing children or other target groups? Part II: cost effectiveness analysis. KCE report 204. 2013. Available at: https://kce.fgov.be/sites/default/files/page_documents/KCE_204_Seasonal_influenza_vaccination_partII.pdf. Accessed Jan 2016.
Van Hoek AJ, et al. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine. 2012;30(6):1225–34.
Van Den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis. 2010;69(Suppl. 1):i89–i91.
Hawthorne G, Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust N Z J Public Health. 2005;29(2):136–42.
Bognar G. Age-weighting. Econ Philos. 2008;24(02):167–89.
Australian Bureau of Statistics (ABS). Life tables, states, territories and Australia, 2011–2013. 2014. Available at: http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3302.0.55.0012011-2013?OpenDocument. Accessed 15 Jun 2015.
Stafoggia M, et al. Summer temperature-related mortality. Epidemiology. 2009;20(4):575–83.
Rocklöv J, Forsberg B, Meister K. Winter mortality modifies the heat-mortality association the following summer. Eur Respir J. 2009;33(2):245–51.
Jit M, Mibei W. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: a critical review. Vaccine. 2015;33(32):3788–94.
Brouwer WBF, et al. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ. 2005;331(7514):446–8.
Vynnycky E, White RG. An introduction to infectious disease modelling. Oxford: Oxford University Press; 2011.
Mossong J, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5(3):0381–91.
Pitsiou GG, Kioumis IP. Pneumococcal vaccination in adults: does it really work? Respir Med. 2011;105(12):1776–83.
Chiu C, Dey A, Wang H. Vaccine preventable diseases in Australia, 2005 to 2007. Commun Dis Intell. 2010;34(Suppl):S1–167.
Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. 2003;70(Suppl. 1):S31–7.